Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Neurology(R) Neuroimmunology & Neuroinflammation|May 15, 2020
Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare systemJennifer Lord, M Mateo Paz Soldan, Jonathan Galli, et al.Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|July 31, 2013
Randomized trial of a presurgical scheduled reduced smoking intervention for patients newly diagnosed with cancerJamie S Ostroff, Jack E Burkhalter, Paul M Cinciripini, et al.BMJ Open|March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemiaAli T Taher, Khaled M Musallam, Vip Viprakasit, et al.European Journal of Cancer (Oxford, England : 1990)|March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trialJohn M Kirkwood, Peter Mohr, Christoph Hoeller, et al.Frontiers in Oncology|February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasmsEsther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.BMJ Open|November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trialAli T Taher, Khaled M Musallam, Vip Viprakasit, et al.Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.Cell|December 12, 2023
APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spreadYun Chen, Sihui Song, Samira Parhizkar, et al.Journal of Clinical Medicine|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 TrialEsther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.Pageof 5